What is OCT‑Angiography (OCT‑A) — and how does it help diagnose AMD and track success in Valeda treatment?
If you’re living with dry age-related macular degeneration (dry AMD), the question that keeps coming up is simple:
“How will I know if it’s staying dry… or turning into wet AMD?”
That moment—when “dry” becomes “wet”—is where eyesight can change quickly. The good news is that modern imaging now allows us to detect vascular change earlier and more precisely than ever before. One of the most important tools in that toolkit is OCT‑angiography (OCT‑A): a non-invasive scan that maps blood flow in the retina and choroid without needing dye injections.
At Peter Ivins Eye Care, OCT‑A is not a “nice extra.” It’s part of our advanced macular disease pathway—used alongside ZEISS CIRRUS 6000, Scotland’s first ZEISS CLARUS 500, and ZEISS Retina Workplace to make sure we see the full picture: structure, blood flow, and change over time.
This post explains:
- what OCT‑A is (in plain English)
- why it matters in both dry and wet AMD
- how OCT‑A can detect “hidden” neovascularisation earlier in some cases
- how we use CIRRUS 6000 AngioPlex, CLARUS 500, and Retina Workplace together
- where OCT‑A fits in the Valeda journey (suitability + monitoring)
Quick takeaway: OCT‑A shows blood flow—OCT shows structure. When you combine both (and track them over time), you’re far better placed to catch AMD change early and manage risk intelligently.
1) What is OCT‑Angiography (OCT‑A)?
OCT‑A in one sentence
OCT‑A is a fast, non-invasive imaging method that uses motion-contrast to visualise blood flow in retinal and choroidal vessels—without dye injection.
How does it work? (the simplest explanation)
A standard OCT takes cross-sectional “slices” of the retina. OCT‑A takes repeated OCT scans in the same spot and looks for tiny signal changes caused by moving red blood cells, building a map of blood flow in different layers of the retina and choroid.
That’s why OCT‑A can show:
- the superficial retinal vessels
- deeper capillary plexuses
- the choriocapillaris (beneath the retina)
- abnormal new vessel growth linked to wet AMD
Because it’s non-invasive, OCT‑A can be repeated frequently—helpful for monitoring and treatment planning—while still requiring careful interpretation because artefacts can occur.
2) Why OCT‑A matters in AMD: spotting the “wet switch” earlier
The key threat: macular neovascularisation (MNV / CNV)
Wet AMD happens when abnormal new vessels grow under or into the retina (often termed choroidal neovascularisation, CNV, or macular neovascularisation, MNV). These vessels can leak fluid or bleed, threatening central vision.
Historically, identifying CNV relied heavily on dye-based angiography (fluorescein/ICG) in secondary care. OCT improved management by revealing fluid patterns that suggest activity. But OCT‑A adds something important: it can visualise the neovascular network itself without dye.
“Looks dry” but isn’t always dry
One of the most clinically useful roles for OCT‑A in AMD is identifying eyes that appear dry on standard examination but may have non-exudative (quiescent) neovascularisation—blood vessels present without obvious leakage yet. This can influence monitoring intensity and referral decisions.
In other words: OCT‑A can help us see vascular risk earlier, even before classic “wet” signs are obvious.
3) How OCT‑A helps in real clinical decision-making
OCT‑A is not just “a fancy picture.” In AMD, it supports several practical outcomes:
A) Detecting CNV/MNV without dye
OCT‑A can identify the presence and pattern of neovascular networks and localise them by depth—supporting earlier detection and more detailed classification compared with structure-only imaging.
B) Supporting monitoring and follow-up strategies
Recent reviews describe OCT‑A as helping with screening and therapy monitoring in AMD, with potential to personalise follow-up—while also emphasising limitations such as artefacts and the need for validation and expert interpretation.
C) Better patient communication
When patients can “see” a vascular network and understand what we’re watching for, it improves engagement and helps explain why we might recommend closer monitoring or referral pathways. OCT‑A lends itself well to that “show and tell” approach, especially when combined with widefield fundus images and OCT.
4) OCT‑A at Peter Ivins Eye Care: why our technology stack matters
In macular disease, quality + consistency + comparability are everything. So we’ve built the Valeda Clinic around imaging that is designed for:
- fast acquisition (less motion artefact)
- high-definition detail
- reliable repeatability over time
- integrated multi-modality review
ZEISS CIRRUS 6000 with AngioPlex OCT‑A
ZEISS CIRRUS 6000 is described as a high-performance OCT platform (100,000 scans per second) with OCT and OCTA capabilities and scan patterns including 12×12 mm single-shot OCTA as well as smaller fields.
ZEISS AngioPlex is positioned as non-invasive imaging of retinal microvasculature, designed to support retinal disease management, including AMD, and to reveal CNV lesions for improved monitoring.
Independent clinical trade coverage also notes CIRRUS 6000 OCTA capture times and workflow improvements (e.g., OCTA capture in under ~10 seconds in one report), reflecting how speed can improve practicality and reduce motion artefact in real clinics.
ZEISS Retina Workplace: longitudinal, integrated review
Retina Workplace is described as integrated multi-modality software enabling registration of ultra-widefield fundus images with OCT‑A, viewing synchronised data in one interface, and comparing multiple exams to detect change over time.
This matters because AMD monitoring isn’t about a single scan—it’s about patterns over time.
ZEISS CLARUS 500: true colour, ultra-widefield context
CLARUS 500 is described as providing true colour and high-resolution imaging across an ultra-widefield image, supporting evaluation from macula to periphery, and offering modalities including fundus autofluorescence (FAF) in addition to colour imaging.
When we combine CLARUS images with OCT/OCT‑A in Retina Workplace, we can correlate “surface” findings (colour) with “depth” findings (OCT) and “flow” findings (OCT‑A) in a single workflow.
5) Where OCT‑A fits in the Valeda pathway (suitability + monitoring)
Valeda photobiomodulation (PBM) pathways rely on careful baseline assessment and structured follow-up. In the broader Valeda evidence ecosystem, imaging outcomes (including OCT and FAF) are explicitly part of ongoing data collection in the EUROLIGHT registry study design.
While OCT‑A is not always necessary for every dry AMD patient, it becomes particularly valuable when we need to:
- clarify whether there is subclinical/non-exudative neovascularisation
- assess vascular changes that could raise suspicion for wet conversion risk
- ensure we’re not missing a “quiet” vascular component in someone thought to be purely dry
This aligns with modern AMD imaging literature describing OCT‑A’s role in identifying underlying nonexudative neovascular disease in eyes that appear dry clinically.
What we’re looking for
During OCT‑A we’re essentially asking:
- Is there any abnormal vessel growth under the macula?
- If yes, does it look stable or suspicious for activity?
- How does this compare to last time? (progression/regression/change)
- Do we need to escalate monitoring or refer?
OCT‑A supports those questions because it can visualise vascular structures in a layered, depth-resolved way, and because it’s repeatable without dye.
6) What happens during an OCT‑A scan?
From a patient perspective, OCT‑A is similar to an OCT:
- you rest your chin and forehead on the device
- you look at a fixation target
- the scan takes seconds
- it’s painless and non-contact
What’s different is that OCT‑A requires a stable fixation for a short period to reduce artefacts. Modern systems emphasise speed and tracking to minimise motion artefact and keep workflow efficient.
7) The important limitations (and why expertise matters)
OCT‑A is powerful—but it’s not magic. Major reviews emphasise that OCT‑A is susceptible to artefacts. Interpretation needs expertise and correlation with other imaging and clinical findings.
That’s precisely why our clinic model focuses on:
- high-quality acquisition
- multi-modality correlation (CLARUS + OCT + OCT‑A)
- longitudinal comparison (Retina Workplace)
- experienced clinical judgement
8) Why patients choose the Valeda Clinic at Peter Ivins Eye Care
Peter Ivins Eye Care is known for leadership in advanced macular diagnostics and being early adopters of technology that makes a clinical difference. With Scotland’s first CLARUS 500 and a connected imaging workflow designed for longitudinal macular monitoring, our approach is built for patients who want proactive care and clarity.
OCT‑A is one part of that: it helps ensure we don’t miss vascular change, and it helps us make smarter monitoring decisions—especially for those with dry AMD who are worried about conversion.
If you have dry AMD, macular changes, drusen, or a family history—and you’re searching for:
- “OCT angiography near Glasgow”
- “OCT‑A for macular degeneration”
- “Valeda clinic Scotland”
- “dry AMD monitoring”
…our team can help you understand your risk, your baseline, and the best next step.
Book now
📞 Call us: 0141 943 3300
📍 Visit our clinic in Bearsden, Glasgow
📅 Book a Valeda Assessment online